Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ABSCFOTCMKTS:CPHRFOTCMKTS:FFNTFOTCMKTS:TGIFF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABSCFAB Science$1.26$1.46$0.80▼$1.60N/AN/A200 shsN/ACPHRFCipher Pharmaceuticals$9.61+1.6%$9.43$6.02▼$14.60N/AN/A14,333 shs4,051 shsFFNTF4Front Ventures$0.00+60.0%$0.00$0.00▼$0.11N/AN/A1.47 million shs74,732 shsTGIFF1933 Industries$0.00+2.2%$0.00$0.00▼$0.01N/AN/A136,907 shs30,157 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABSCFAB Science0.00%0.00%-21.25%-19.75%-53.33%CPHRFCipher Pharmaceuticals0.00%+4.00%+7.37%+11.74%+59.56%FFNTF4Front Ventures0.00%+700.00%+300.00%-84.31%-98.00%TGIFF1933 Industries0.00%-14.55%+4.44%+34.29%-53.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABSCFAB ScienceN/AN/AN/AN/AN/AN/AN/AN/ACPHRFCipher PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/AN/AN/AN/ATGIFF1933 IndustriesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABSCFAB Science 0.00N/AN/AN/ACPHRFCipher Pharmaceuticals 0.00N/AN/AN/AFFNTF4Front Ventures 0.00N/AN/AN/ATGIFF1933 Industries 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABSCFAB ScienceN/AN/AN/AN/AN/AN/ACPHRFCipher PharmaceuticalsN/AN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/AN/ATGIFF1933 IndustriesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABSCFAB ScienceN/AN/A0.00∞N/AN/AN/AN/AN/ACPHRFCipher PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/A8/7/2025 (Estimated)FFNTF4Front VenturesN/AN/A0.00∞N/AN/AN/AN/AN/ATGIFF1933 IndustriesN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABSCFAB ScienceN/AN/AN/AN/AN/ACPHRFCipher PharmaceuticalsN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/ATGIFF1933 IndustriesN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABSCFAB ScienceN/ACPHRFCipher Pharmaceuticals25.09%FFNTF4Front VenturesN/ATGIFF1933 IndustriesN/AInsider OwnershipCompanyInsider OwnershipABSCFAB ScienceN/ACPHRFCipher PharmaceuticalsN/AFFNTF4Front VenturesN/ATGIFF1933 IndustriesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABSCFAB Science51N/AN/ANot OptionableCPHRFCipher Pharmaceuticals5N/AN/ANot OptionableFFNTF4Front Ventures460N/AN/ANot OptionableTGIFF1933 Industries87N/AN/ANot OptionableCPHRF, TGIFF, FFNTF, and ABSCF HeadlinesRecent News About These Companies1933 Industries Reports Profit in Q3 2025 Amidst Industry ChallengesJune 16, 2025 | tipranks.com1933 Industries Reports Profit in Third Quarter 2025 Financial ResultsJune 16, 2025 | accessnewswire.comA1933 Industries Completes Full Acquisition of AMA SubsidiaryJune 2, 2025 | tipranks.com1933 Industries Announces the Completion of the Purchase of 9% Interest of Cultivation and Production SubsidiaryJune 2, 2025 | accessnewswire.comA1933 Industries Completes Acquisition of Remaining Interest in SubsidiaryMay 22, 2025 | tipranks.com1933 Industries To Complete Purchase of 9% Interest of Cultivation and Production SubsidiaryMay 22, 2025 | accessnewswire.comA1933 Industries Stock Short Interest Report | OTC:TGIFF | BenzingaApril 21, 2025 | benzinga.com1933 sees uptick in revenue in NevadaApril 2, 2025 | greenmarketreport.comG1933 Industries Reports Second Quarter 2025 Financial ResultsMarch 31, 2025 | accessnewswire.comACSE Bulletin: Reinstatement - 1933 Industries Inc. (TGIF)March 6, 2025 | newsfilecorp.comN1933 Industries Inc.: 1933 Industries Announces First Quarter 2025 Financial ReportFebruary 28, 2025 | finanznachrichten.de1933 Industries Announces First Quarter 2025 Financial ReportFebruary 27, 2025 | accessnewswire.comA1933 Industries Inc.: 1933 Industries Announces Fourth Quarter and 2024 Year-End Financial Results with Record Revenues of $19.3 MillionFebruary 27, 2025 | finanznachrichten.de1933 Industries losses contract year-over-year, but company still in the redFebruary 26, 2025 | greenmarketreport.comG1933 Industries Announces Fourth Quarter and 2024 Year-End Financial Results with Record Revenues of $19.3 MillionFebruary 25, 2025 | accessnewswire.comA1933 Industries Appoints New CFO and VP FinanceJanuary 31, 2025 | accessnewswire.comA1933 Industries Provides Update on Status of Filing Delay for 4th Quarterly ReportJanuary 24, 2025 | accessnewswire.comA1933 Industries Inc.: 1933 Industries Provides Update on Status of Filing Delay for 4th Quarterly Report and Announces Management ChangesJanuary 11, 2025 | finanznachrichten.de1933 Industries Provides Update on Status of Filing Delay for 4th Quarterly Report and Announces Management ChangesJanuary 11, 2025 | markets.businessinsider.com1933 Industries Inc.: 1933 Industries Provides Update on Status of Filing Delay for 4th Quarterly ReportDecember 27, 2024 | finanznachrichten.deMedia Sentiment Over TimeCPHRF, TGIFF, FFNTF, and ABSCF Company DescriptionsAB Science OTCMKTS:ABSCF$1.26 0.00 (0.00%) As of 07/3/2025AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.Cipher Pharmaceuticals OTCMKTS:CPHRF$9.61 +0.16 (+1.64%) As of 07/3/2025 12:32 PM EasternCipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.4Front Ventures OTCMKTS:FFNTF$0.0016 +0.00 (+60.00%) As of 07/3/2025 11:42 AM Eastern4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates through THC Cannabis and CBD Wellness segments. THC Cannabis segment engages in the cultivation, production, manufacturing, and distribution of THC cannabis products to owned dispensaries and third party retailers; and provision of ancillary services. This segment sells equipment, supplies, and intellectual property to cannabis producers; and leases real estate properties. The CBD Wellness segment sells non-THC hemp derived products. In addition, it operates dispensaries in the Massachusetts, Illinois, and Michigan primarily under the MISSION brand name. 4Front Ventures Corp. was founded in 2011 and is based in Phoenix, Arizona.1933 Industries OTCMKTS:TGIFF$0.0047 +0.00 (+2.17%) As of 07/3/2025 11:26 AM Eastern1933 Industries Inc., together with its subsidiaries, engages in the cultivation and production of cannabis products in the United States. It operates in three segments: the Medical Segment, the Recreational Segment, and the CBD-Infused Products Segment. The company produces, packages, and markets cannabidiol (CBD)-infused products, including tinctures, vape pens and cartridges, lotions, pain creams, gummies, and capsules under the Canna Hemp and Canna Hemp X brand names. It also offers craft-style cannabis, infused pre-rolls, full spectrum oils, distillates, terpenes, and vaporizer products; and boutique concentrates, such as shatters, crumbles, batters, sugar waxes, diamonds, and cured and live resins under the AMA and Level X brand names. The company offers its products through retail dispensaries and retail outlets, as well as through its e-commerce platform. The company was formerly known as Friday Night Inc. and changed its name to 1933 Industries Inc. in September 2018. 1933 Industries Inc. is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
